Related Experiment Video
Updated: Jun 10, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
The downstream purification of bispecific antibodies
Qian Li1, Hongyang Zhao1, Xiaoying Liang1
1Nanjing Chia-Tai Tianqing Pharmaceutical Co.Ltd, Fanghua Research Institute, Institute of Biology, Nanjing, 210046, China.
Abstract:
Bispecific antibodies, a class of therapeutic antibodies, can simultaneously bind to two distinct targets. Compared with monospecific antibodies, bispecific antibodies offer advantages, including superior efficacy and reduced side effects. However, because of their structural complexity, the purification of bispecific antibodies is highly challenging. The purification process must strike a delicate balance between purity and productivity, eliminating a broad spectrum of contaminants, including product-related and process-related impurities, while also maximizing the yield wherever feasible. This review systematically describes the strategies for bispecific antibody capture, the elimination of product-related impurities, and the mitigation of the formation of process-related impurities, thereby, providing guidance for the development of downstream purification processes for bispecific antibodies.
Related Concept Videos
Immunoprecipitation
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

